AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

A reasonable strategy for drug therapy of non-small-cell lung cancer  (NSCLC) with activating mutations of EGFR is the use of tyrosine kinase inhibitors (TKI) in front-line therapy, providing a two-fold increase in life expectancy for patients with metastatic or locally advanced form of the disease....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: E. V. Karabina, L. N. Lubchenko, M. M. Davydov
Formato: Artigo
Idioma:Russo
Publicado em: Remedium Group LLC 2017-11-01
Colecção:Медицинский совет
Assuntos:
locally advanced and metastatic non-small cell lung cancer
adenocarcinoma of the lung
tyrosine kinase inhibitors of egfr
egfr-activating mutations
targeted therapy
resistance
afatinib
Acesso em linha:https://www.med-sovet.pro/jour/article/view/2166
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados